Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Transcode Therapeutics Inc (RNAZ)

Transcode Therapeutics Inc (RNAZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,657
  • Shares Outstanding, K 917
  • Annual Sales, $ 0 K
  • Annual Income, $ -16,750 K
  • EBIT $ -17 M
  • EBITDA $ -17 M
  • 60-Month Beta 1.52
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.03

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.20 +1.71%
on 12/03/25
9.85 -15.33%
on 11/10/25
-1.09 (-11.58%)
since 11/07/25
3-Month
8.20 +1.71%
on 12/03/25
20.99 -60.27%
on 10/08/25
-2.81 (-25.20%)
since 09/09/25
52-Week
6.15 +35.64%
on 04/17/25
468.44 -98.22%
on 01/28/25
-202.50 (-96.04%)
since 12/09/24

Most Recent Stories

More News
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

Accomplished drug development leader to advance TransCode's mission of defeating cancer through RNA innovation and translational excellence

RNAZ : 8.34 (-0.12%)
TransCode Therapeutics Completes Phase 1a Trial for TTX-MC138

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. TransCode...

RNAZ : 8.34 (-0.12%)
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO

BOSTON , Oct. 14, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announces completion of Phase 1a clinical trial with TTX-MC138, an investigational inhibitor of microRNA-10b, or...

RNAZ : 8.34 (-0.12%)
TransCode Therapeutics Acquires Polynoma and Secures Investment

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. TransCode...

RNAZ : 8.34 (-0.12%)
TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company

BOSTON and SAN DIEGO , Oct. 8, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) ("TransCode or the "Company") announced today that it entered into a definitive agreement to acquire...

RNAZ : 8.34 (-0.12%)
TransCode Therapeutics Amends Patent License Agreement

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. TransCode...

RNAZ : 8.34 (-0.12%)
TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138

TransCode Therapeutics (NASDAQ: RNAZ) reported continued progress in its Phase 1a trial of TTX-MC138, an RNA-based therapeutic targeting microRNA-10b in metastatic cancer. Thirteen patients have received...

RNAZ : 8.34 (-0.12%)
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split Effective December 4, 2024

TransCode Therapeutics will implement a 1-for-33 reverse stock split effective December 4, 2024, to maintain Nasdaq listing requirements.Quiver AI SummaryTransCode Therapeutics, Inc. announced a 1-for-33...

RNAZ : 8.34 (-0.12%)
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

RNAZ : 8.34 (-0.12%)
TransCode Therapeutics, Inc. Announces $8 Million Private Placement Agreement with Institutional Investors

TransCode Therapeutics announces an $8 million private placement of common stock and warrants for general corporate purposes.Quiver AI SummaryTransCode Therapeutics, Inc. has announced a securities purchase...

RNAZ : 8.34 (-0.12%)

Business Summary

TransCode Therapeutics is an emerging RNA oncology company. Its platform of investigational drug candidates is dedicated to improving patient outcomes encompassing a variety of tumor types. The company's lead therapeutic candidate includes TTX-MC138. TransCode Therapeutics is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 9.06
2nd Resistance Point 8.87
1st Resistance Point 8.61
Last Price 8.34
1st Support Level 8.17
2nd Support Level 7.98
3rd Support Level 7.72

See More

52-Week High 468.44
Fibonacci 61.8% 291.84
Fibonacci 50% 237.29
Fibonacci 38.2% 182.74
Last Price 8.34
52-Week Low 6.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar